iStock_37438014_XXXLARGE-outlined_LM.png pink_scrubs.png hp-people-3.png man-in-sweater_90824869_v1MAG.png Dr-Glasses.png iStock_86712797_XXXLARGE-outline_LM.png blue_shirt_masthead_man_v1_MAG.png NKT-hp-people-Michelle_v1_LM.png iStock_68713947_XXLARGE-outiline_LM.png NKT-hp-people-Phi_v1_LM.png NKT-hp-people-Mekhala_v1_LM.png hp-people-3.png iStock_87627749_XXXLARGE-outline_LM.png

Events

AUG 08

Q2 2019 Financial Results Conference Call
San Francisco, CA
2:00 p.m. PDT/ 5:00 p.m. EDT

Webcast Link

JUN 13

Analyst Call with Immunology Expert at 2019 EULAR
Madrid, Spain
8:00 a.m. EDT

Webcast Link
Presentation Slides

MAR 01

Analyst Call at ASCO-SITC
San Francisco, CA
3:00 p.m. PT

Webcast Link 

Presentation Slides

Leadership Spotlight

Dr. Jonathan Zalevsky, Chief Scientific Officer discusses bempegaldesleukin (NKTR-214)

Watch

Latest News

OUR PIPELINE

We are focused on using new chemistry approaches to make better medicines to treat cancer, chronic pain and auto-immune disease.

Bempegaldesleukin

IMMUNO-ONCOLOGY

Phase 3

  • 9

    9 million patients benefit from our medicines

    9
    9
    9
  • 12

    12 approved products around the world

    12
    12
    12
  • 10

    10 new medicines in development pipeline

    10
    10
    10


Cutting-edge facilities




Dynamic teams




Impactful work


OUR Culture

We are supported by a dynamic team, rich in scientific, business and medical expertise, across three locations.

Read more